Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Penelope D, Ottewell"'
Autor:
Mai Morita, Fawaz Arshad, Lewis A. Quayle, Christopher N. George, Diane V. Lefley, Ivo Kalajzic, Meena Balsubramanian, Tugba Cebe, Gwen Reilly, Nicolas J. Bishop, Penelope D. Ottewell
Publikováno v:
Bone Reports, Vol 22, Iss , Pp 101795- (2024)
Excessive production of Transforming Growth Factor β (TGFβ) is commonly associated with dominant and recessive forms of OI. Previous reports have indicated that administration of TGFβ-targeted antibodies maybe of potential therapeutic benefit to O
Externí odkaz:
https://doaj.org/article/a7a0cce7a6dc4695a9b672b575366fde
Autor:
Jiabao Zhou, Penelope D. Ottewell
Publikováno v:
Journal of Bone Oncology, Vol 46, Iss , Pp 100608- (2024)
Interleukin-1B (IL-1B) is a potent pro-inflammatory cytokine that plays multiple, pivotal roles, in the complex interplay between breast cancer cells and the bone microenvironment. IL-1B is involved in the growth of the primary tumours, regulation of
Externí odkaz:
https://doaj.org/article/b6b36135be8a4951b467f2dee4841d99
Autor:
Amy Kwan, Faith Howard, Natalie Winder, Emer Atkinson, Ameera Jailani, Priya B. Patel, Richard Allen, Penelope D. Ottewell, Gary C. Shaw, Joe Conner, Caroline Wilson, Sanjay K. Srivastava, Sarah J. Danson, Claire Lewis, Janet E. Brown, Munitta Muthana
Publikováno v:
Future Pharmacology, Vol 2, Iss 4, Pp 444-459 (2022)
Oncolytic viruses (OV) promote anti-tumour responses through the initiation of immunogenic cancer cell death which activates the host’s systemic anti-tumour immunity. We have previously shown that intravenously administered HSV1716 is an effective
Externí odkaz:
https://doaj.org/article/3b4d26e88bfb46238c249a242f2891a1
Autor:
Claudia Tulotta, Diane V. Lefley, Charlotte K. Moore, Ana E. Amariutei, Amy R. Spicer-Hadlington, Lewis A. Quayle, Russell O. Hughes, Khawla Ahmed, Victoria Cookson, Catherine A. Evans, Jayakumar Vadakekolathu, Paul Heath, Sheila Francis, Emmanuel Pinteaux, A. Graham Pockley, Penelope D. Ottewell
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-15 (2021)
Abstract Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that production of the pro-inflamm
Externí odkaz:
https://doaj.org/article/db7c85c82ea947e69d237a3402f52c96
Autor:
Rachel Eyre, Denis G. Alférez, Angélica Santiago-Gómez, Kath Spence, James C. McConnell, Claire Hart, Bruno M. Simões, Diane Lefley, Claudia Tulotta, Joanna Storer, Austin Gurney, Noel Clarke, Mick Brown, Sacha J. Howell, Andrew H. Sims, Gillian Farnie, Penelope D. Ottewell, Robert B. Clarke
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
In breast cancer, dormant cancer cells may develop into bone metastases. Here, the authors demonstrate that microenvironmental IL1β stimulates metastatic breast cancer cell colonisation in the bone via IL1β-NFKB/CREB-Wnt pathway activation and canc
Externí odkaz:
https://doaj.org/article/c9b7748a363e46eb80d945fea7c4be66
Autor:
Victor G. Canuas-Landero, Christopher N. George, Diane V. Lefley, Hannah Corness, Munitta Muthana, Caroline Wilson, Penelope D. Ottewell
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Clinical trials have demonstrated that adding zoledronic acid (Zol) to (neo)adjuvant standard of care has differential antitumour effects in pre- and post-menopausal women: Both benefit from reduced recurrence in bone; however, while postmenopausal w
Externí odkaz:
https://doaj.org/article/bacfe60dab50449a89369bedf253a759
Autor:
Gloria Allocca, Russell Hughes, Ning Wang, Hannah K Brown, Penelope D Ottewell, Nicola J Brown, Ingunn Holen
Publikováno v:
Journal of Bone Oncology, Vol 17, Iss , Pp - (2019)
Background: Bone metastasis is one of the most common complications of advanced breast cancer. During dissemination to bone, breast cancer cells locate in a putative ‘metastatic niche’, a microenvironment that regulates the colonisation, maintena
Externí odkaz:
https://doaj.org/article/12c2aea1c17749b38ad1953739c04483
Autor:
Lubaid Saleh, Penelope D. Ottewell, Janet E. Brown, Steve L. Wood, Nichola J. Brown, Caroline Wilson, Catherine Park, Simak Ali, Ingunn Holen
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2211
CDK 4/6 inhibitors have demonstrated significant improved survival for patients with estrogen receptor (ER) positive breast cancer (BC). However, the ability of these promising agents to inhibit bone metastasis from either ER+ve or triple negative BC
Autor:
Ingunn Holen, Colby L. Eaton, Peter I. Croucher, C. Anne Fowles, Kimberly J. Reeves, Hannah K. Brown, Ning Wang, Penelope D. Ottewell
Purpose: Clinical trials in early breast cancer have suggested that benefits of adjuvant bone-targeted treatments are restricted to women with established menopause. We developed models that mimic pre- and postmenopausal status to investigate effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93ee6911ebb9a86d5820ae7b1a1b8555
https://doi.org/10.1158/1078-0432.c.6521501.v1
https://doi.org/10.1158/1078-0432.c.6521501.v1
Autor:
Ingunn Holen, Colby L. Eaton, Peter I. Croucher, C. Anne Fowles, Kimberly J. Reeves, Hannah K. Brown, Ning Wang, Penelope D. Ottewell
PDF file - 50KB, Numbers of MDA-MB-231 cells present in long bones of 12 week old mice 24h after inter-cardiac injection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::923e7a8a298265529489de834df62241
https://doi.org/10.1158/1078-0432.22448870.v1
https://doi.org/10.1158/1078-0432.22448870.v1